Medtronic acquires Israel?s Ventor as part of $1.03b heart valve shopping spreeIsrael’s Ventor Technologies, a developer of transcatheter heart valve technologies for the treatment of aortic valve disease, will be acquired by Medtronic for $325 million. The acquisition is one of two Medtronic is executing; it will also purchase CoreValve for $700 million or $1.03 billion in total. The Ventor acquisition adds two more technologies to Medtronic’s transcatheter valve portfolio: a minimally invasive, surgical transapical technology and a next generation percutaneous transfemoral technology. ISRAEL21c last week reported on the impending deal.